Skip to main content
. Author manuscript; available in PMC: 2023 Sep 22.
Published in final edited form as: Biosci Trends. 2023 Mar 9;17(2):126–135. doi: 10.5582/bst.2023.01022

Figure 3. The identification of interaction between ERp57 and PGRN/ND7.

Figure 3.

(A) The interactions between ERp57 and PGRN/ND7, assayed by solid phase binding. Briefly, 1 μg/mL ERp57 or BSA was coated to the plate. Then biotin-labeled BSA, PGRN, or ND7 with differing doses (0, 1, 2, 5 μg/mL) were added as bait. (B) The interactions between ERp57 and PGRN by solid phase binding using recombinant ERp57 with different dose (0.2, 0.5, 1, 2, 4 μg/mL) as bait, and 1 μg/mL recombinant PGRN or BSA was used as coating protein. (C) Co-IP assay was used to examine the binding between PGRN and ERp57 in vivo. HEK293 cells were transfected with plasmids encoding GFP-fused full-length PGRN or ND7. The cell lysates were immunoprecipitated with GFP antibody. The complex was probed with ERp57 antibody. GFP-fused vector was used as a control. (D) Examination of the binding between PGRN and ERp57. Proteins co-purified with His-tagged PGRN were probed with ERp57 antibody. HEK293 cells transfected with His-tag vector was used as control.